2024
Relationships Between Retinal Amyloid Imaging and Amyloid PET in the A4 Trial
Rissman R, Ngolab J, Donohue M, Belsha A, Salazar J, Cohen P, Jaiswal S, Tan V, Aggarwal N, Alber J, Johnson K, Jicha G, van Dyck C, Lah J, Salloway S, Rafii M, Aisen P, Sperling R. Relationships Between Retinal Amyloid Imaging and Amyloid PET in the A4 Trial. Alzheimer's & Dementia 2024, 20: e090880. PMCID: PMC11716286, DOI: 10.1002/alz.090880.Peer-Reviewed Original ResearchA4 trialFeasibility of retinal imagingPositron emission tomographyAmyloid positron emission tomographyLongitudinal Evaluation of Amyloid RiskRetinal spotsCohort of individualsAnti-Amyloid TreatmentAsymptomatic Alzheimer's diseaseRetinal amyloid depositsAlzheimer's diseaseStandardized uptake value ratioAD-diagnosed patientsPilot studyRetinal imaging techniquesLongitudinal evaluationRisk detectionNon-invasive evaluationAmyloid depositsClinically normal individualsAnti-amyloidRetinal amyloid imagingParticipantsPET standardized uptake value ratioRetinal fundus images
2023
Feasibility Study for Longitudinal Retinal Imaging in the Anti‐Amyloid Treatment in Asymptomatic Alzheimer’s Disease (A4) Trial
Rissman R, Ngolab J, Donohue M, Belsha A, Salazar J, Cohen P, Jaiswal S, Tan V, Aggarwal N, Alber J, Johnson K, Jicha G, van Dyck C, Lah J, Salloway S, Rafii M, Aisen P, Sperling R. Feasibility Study for Longitudinal Retinal Imaging in the Anti‐Amyloid Treatment in Asymptomatic Alzheimer’s Disease (A4) Trial. Alzheimer's & Dementia 2023, 19 DOI: 10.1002/alz.079580.Peer-Reviewed Original ResearchAnti-Amyloid TreatmentAsymptomatic Alzheimer's diseaseFeasibility of retinal imagingLongitudinal Evaluation of Amyloid RiskCohort of individualsAlzheimer's diseaseResults ParticipantsAnti-amyloidA4 trialAD-diagnosed patientsRetinal spotsPositron emission tomographyStandardized uptake value ratioAmyloid positron emission tomographyLongitudinal evaluationRisk detectionClinically normal individualsParticipantsPET standardized uptake value ratioFeasibility studyClinicCross-sectionRetinal amyloid depositsAmyloid depositsIndividualsLongitudinal head-to-head comparison of 11C-PiB and 18F-florbetapir PET in a Phase 2/3 clinical trial of anti-amyloid-β monoclonal antibodies in dominantly inherited Alzheimer’s disease
Chen C, McCullough A, Gordon B, Joseph-Mathurin N, Flores S, McKay N, Hobbs D, Hornbeck R, Fagan A, Cruchaga C, Goate A, Perrin R, Wang G, Li Y, Shi X, Xiong C, Pontecorvo M, Klein G, Su Y, Klunk W, Jack C, Koeppe R, Snider B, Berman S, Roberson E, Brosch J, Surti G, Jiménez-Velázquez I, Galasko D, Honig L, Brooks W, Clarnette R, Wallon D, Dubois B, Pariente J, Pasquier F, Sanchez-Valle R, Shcherbinin S, Higgins I, Tunali I, Masters C, van Dyck C, Masellis M, Hsiung R, Gauthier S, Salloway S, Clifford D, Mills S, Supnet-Bell C, McDade E, Bateman R, Benzinger T. Longitudinal head-to-head comparison of 11C-PiB and 18F-florbetapir PET in a Phase 2/3 clinical trial of anti-amyloid-β monoclonal antibodies in dominantly inherited Alzheimer’s disease. European Journal Of Nuclear Medicine And Molecular Imaging 2023, 50: 2669-2682. PMID: 37017737, PMCID: PMC10330155, DOI: 10.1007/s00259-023-06209-0.Peer-Reviewed Original ResearchConceptsStandardized uptake value ratioPhase 2/3 clinical trialsPositron emission tomographyAnti-Aβ monoclonal antibodyClinical trialsPlacebo armDrug effectsLongitudinal changesMonoclonal antibodiesGlobal cortical standardized uptake value ratioHead comparisonCortical standardized uptake value ratioRegional standardized uptake value ratiosAβ positron emission tomographyAmyloid-β positron emission tomographyAlzheimer's disease clinical trialsPET imagingUptake value ratioAβ PET imagingSimulated clinical trialTwo-sample t-testDrug armPittsburgh CompoundPET scansWelch two sample t-test
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply